GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (NAS:SQNM) » Definitions » Asset Turnover

Sequenom (Sequenom) Asset Turnover : 0.29 (As of Jun. 2016)


View and export this data going back to 2000. Start your Free Trial

What is Sequenom Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Sequenom's Revenue for the three months ended in Jun. 2016 was $29.3 Mil. Sequenom's Total Assets for the quarter that ended in Jun. 2016 was $101.0 Mil. Therefore, Sequenom's Asset Turnover for the quarter that ended in Jun. 2016 was 0.29.

Asset Turnover is linked to ROE % through Du Pont Formula. Sequenom's annualized ROE % for the quarter that ended in Jun. 2016 was 48.32%. It is also linked to ROA % through Du Pont Formula. Sequenom's annualized ROA % for the quarter that ended in Jun. 2016 was -24.99%.


Sequenom Asset Turnover Historical Data

The historical data trend for Sequenom's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequenom Asset Turnover Chart

Sequenom Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.24 0.61 0.99 0.92

Sequenom Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.23 0.23 0.25 0.29

Competitive Comparison of Sequenom's Asset Turnover

For the Biotechnology subindustry, Sequenom's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequenom's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sequenom's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Sequenom's Asset Turnover falls into.



Sequenom Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Sequenom's Asset Turnover for the fiscal year that ended in Dec. 2015 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2015 )/( (Total Assets (A: Dec. 2014 )+Total Assets (A: Dec. 2015 ))/ count )
=128.282/( (161.071+118.782)/ 2 )
=128.282/139.9265
=0.92

Sequenom's Asset Turnover for the quarter that ended in Jun. 2016 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2016 )/( (Total Assets (Q: Mar. 2016 )+Total Assets (Q: Jun. 2016 ))/ count )
=29.287/( (104.616+97.329)/ 2 )
=29.287/100.9725
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Sequenom  (NAS:SQNM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Sequenom's annulized ROE % for the quarter that ended in Jun. 2016 is

ROE %**(Q: Jun. 2016 )
=Net Income/Total Stockholders Equity
=-25.228/-52.2055
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-25.228 / 117.148)*(117.148 / 100.9725)*(100.9725/ -52.2055)
=Net Margin %*Asset Turnover*Equity Multiplier
=-21.54 %*1.1602*-1.9341
=ROA %*Equity Multiplier
=-24.99 %*-1.9341
=48.32 %

Note: The Net Income data used here is four times the quarterly (Jun. 2016) net income data. The Revenue data used here is four times the quarterly (Jun. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Sequenom's annulized ROA % for the quarter that ended in Jun. 2016 is

ROA %(Q: Jun. 2016 )
=Net Income/Total Assets
=-25.228/100.9725
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-25.228 / 117.148)*(117.148 / 100.9725)
=Net Margin %*Asset Turnover
=-21.54 %*1.1602
=-24.99 %

Note: The Net Income data used here is four times the quarterly (Jun. 2016) net income data. The Revenue data used here is four times the quarterly (Jun. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Sequenom Asset Turnover Related Terms

Thank you for viewing the detailed overview of Sequenom's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequenom (Sequenom) Business Description

Traded in Other Exchanges
N/A
Address
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
Executives
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Kenneth F Buechler director
Charles P Slacik director 250 S. KRAEMER BLVD, BREA CA 92821
Jeffrey D Linton officer: Sr VP, GC & Secretary 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Carolyn Beaver officer: SVP & CFO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Benjamin R Miller director 430 SOUTH SPRING STREET, BURLINGTON NC 27215
William Haas director
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Eberts F Samuel Iii director, officer: Chairman, President & Sec 22 W FRONTAGE ROAD, NORTHFIELD IL 60093
Glenn A Eisenberg director, officer: EVP and Treasurer P O BOX 1017, CHARLOTTE NC 28201-1017
Van Der Vaart Sandra D director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
David Pendarvis director REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
William J Welch officer: President & CEO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121

Sequenom (Sequenom) Headlines

From GuruFocus

Gurus Hold Five-Year Lows in Biotech, Utilities

By Sally Jones Sally Jones 09-20-2013

Context Capital Management's Top Buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-15-2015

Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares

By GuruFocus GuruFocus 08-03-2012

Sequenom Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-05-2010

Sequenom Officer Acquires 30,000 Shares

By Jennifer Chiou Jennifer Chiou 05-10-2016

Sequenom Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010